Please login to the form below

Not currently logged in
Email:
Password:

The Liver Meeting 2019

This page shows the latest The Liver Meeting 2019 news and features for those working in and with pharma, biotech and healthcare.

Novartis makes case for NASH candidate tropifexor

Novartis makes case for NASH candidate tropifexor

This condition is a type of non-alcoholic fatty liver disease (NAFLD), which causes an accumulation of fat in the liver which leads to chronic inflammation and fibrosis. ... The full, detailed data is due to be presented at The Liver Meeting 2019 taking

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Iguazu

Iguazu Ltd is a digital healthcare agency, delivering tactical and innovative solutions. WHAT WE DO We are Closed Loop Marketing...

Latest intelligence

Emre Vural
Sourcing R&D innovation: why pharma companies need to evolve their business models
Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
Gilead Headquarters
The search for effective drug treatments for COVID-19
PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...

Infographics